These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15186726)

  • 21. Renal cell carcinoma and natural killer cells: studies in a novel rat model in vitro and in vivo.
    Winter BK; Wu S; Nelson AC; Pollack SB
    Cancer Res; 1992 Nov; 52(22):6279-86. PubMed ID: 1423274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
    Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
    Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocyte therapy of renal cell carcinoma.
    Dillman RO
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cell-based immunotherapeutic strategies.
    Klingemann HG
    Cytotherapy; 2005; 7(1):16-22. PubMed ID: 16040380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
    Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
    Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.
    Wittnebel S; Da Rocha S; Giron-Michel J; Jalil A; Opolon P; Escudier B; Validire P; Khawam K; Chouaib S; Azzarone B; Caignard A
    Cancer Res; 2007 Jun; 67(12):5594-9. PubMed ID: 17575122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated allogeneic NK cells as suppressors of alloreactive responses.
    Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic stem cell transplantation for renal cell carcinoma.
    Bregni M; Herr W; Blaise D;
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):901-11. PubMed ID: 21707287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma.
    Frohn C; Doehn C; Durek C; Böhle A; Schlenke P; Jocham D; Kirchner H
    J Immunother; 2000; 23(4):499-504. PubMed ID: 10916760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
    Kim DH; Sohn SK; Lee NY; Baek JH; Kim JG; Won DI; Suh JS; Lee KB; Shin IH
    Eur J Haematol; 2005 Oct; 75(4):299-308. PubMed ID: 16146536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of patients with advanced cancer with the natural killer cell line NK-92.
    Tonn T; Schwabe D; Klingemann HG; Becker S; Esser R; Koehl U; Suttorp M; Seifried E; Ottmann OG; Bug G
    Cytotherapy; 2013 Dec; 15(12):1563-70. PubMed ID: 24094496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice.
    Frings PW; Van Elssen CH; Wieten L; Matos C; Hupperets PS; Schouten HC; Bos GM; van Gelder M
    Breast Cancer Res Treat; 2011 Dec; 130(3):773-81. PubMed ID: 21274621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
    Schleypen JS; Baur N; Kammerer R; Nelson PJ; Rohrmann K; Gröne EF; Hohenfellner M; Haferkamp A; Pohla H; Schendel DJ; Falk CS; Noessner E
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):718-25. PubMed ID: 16467081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation.
    Perlingeiro Beltrame M; Malvezzi M; Bonfim C; Covas DT; Orfao A; Pasquini R
    Cytotherapy; 2014 Jul; 16(7):976-89. PubMed ID: 24831839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural killer cells as a therapeutic tool in mismatched transplantation.
    Ruggeri L; Capanni M; Mancusi A; Aversa F; Martelli MF; Velardi A
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):427-38. PubMed ID: 15498714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
    Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Frequency of Post-Transfusion Microchimerism Among Multi-Transfused Beta-Thalassemic Patients.
    Matsagos S; Verigou E; Kourakli A; Alexis S; Vrakas S; Argyropoulou C; Lazaris V; Spyropoulou P; Labropoulou V; Georgara N; Lykouresi M; Karakantza M; Alepi C; Symeonidis A
    Front Med (Lausanne); 2022; 9():845490. PubMed ID: 35252277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.
    Ohira M; Hotta R; Tanaka Y; Matsuura T; Tekin A; Selvaggi G; Vianna R; Ricordi C; Ruiz P; Nishida S; Tzakis AG; Ohdan H
    Cancer Immunol Immunother; 2022 Mar; 71(3):589-599. PubMed ID: 34282496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.